Takeda buys vaccine maker LigoCyte
(Reuters) - Japan's Takeda Pharmaceutical Co Ltd (4502.T) said it would buy privately held U.S. company LigoCyte Pharmaceuticals Inc for an upfront payment of $60 million to expand its vaccine portfolio.
The deal gives Takeda access to LigoCyte's experimental norovirus vaccine. The virus is the most common cause of gastroenteritis, a swelling of the gastrointestinal tract.
LigoCyte is also developing experimental vaccines against respiratory syncytial virus, influenza and rotavirus.
Takeda intends to retain LigoCyte's management team and its employees as part of the deal, which also includes additional milestone payments based on the progress of LigoCyte's development programs.
(Reporting by Vidya P L Nathan; Editing by Supriya Kurane)
WASHINGTON - The Federal Reserve on Wednesday embarked on the risky task of winding down the era of easy money, saying the U.S. economy was finally strong enough for it to start scaling down its massive bond-buying stimulus. | Video
WASHINGTON - Start-up companies will be able to raise much more capital through certain public stock deals without facing costly regulatory burdens under a proposal announced by U.S. securities regulators on Wednesday.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.